Tag - CytoAgents

CytoAgents’ Phase 1 Trial Results Show “Cytokine Release Syndrome” Drug Candidate Safe

Ziad2022-11-25T14:00:28-05:00 Successful Completion of Phase 1 Clinical Trial, Close of Initial Equity Round of Funding, and Addition of Dr. Stanley Marks and John Friedman to Board of Directors Positions CytoAgents for Larger Series A and Phase II Trials. Read more >>

15 Pittsburgh tech companies to watch in 2021

Ziad2022-11-25T14:02:04-05:00 CytoAgents on list of top 15 Pittsburgh tech companies to watch in 2021. Read more >>

Wolf Administration Highlights Development of Promising New Drug Candidate to Treat COVID-19

Ziad2022-11-25T14:02:04-05:00 On Wednesday, Department of Community and Economic Development (DCED) Deputy Secretary Steve D’Ettorre and Ben Franklin Technology Partners Innovation Works Chief Executive Officer Richard Lunak joined Teresa Whalen, CEO of Pittsburgh-based CytoAgents, to highlight the development of a new COVID-19 treatment. “This exciting new development was made possible by the strong partnerships the Wolf Administration has fostered with our Ben Franklin Technology Partners and the companies they support, like CytoAgents,” said D’Ettorre. Read more >>

Pittsburgh-based company behind ‘promising’ new COVID-19 treatment

Ziad2022-11-25T14:02:04-05:00 On Wednesday, the Wolf Administration plans to highlight what it calls in a news advisory a “promising new drug candidate to treat COVID-19.” The Department of Community and Economic Development will announce that Pittsburgh-based biotechnology company CytoAgents has begun its Phase 1 clinical trial for COVID-19 treatment. Read more >>

How CytoAgents’ plans for growth run far beyond Covid crisis

Ziad2022-11-25T14:02:04-05:00 GP1681 “has the potential to be the next best practice in medicine in areas with significant unmet need,” CytoAgents CEO Teresa Whalen said. Out clinical trials as well as plans for growth to include other uses for the dreuge. CytoAgents is working in Australia with its partner, Novotech, on the phase one clinical trial of GP1681...Read more >>

Teresa Whalen talks about CytoAgents and the treatment of Cytokine Storm

Ziad2022-11-25T14:02:05-05:00 Teresa Whalen is the CEO of CytoAgents, a startup focused on the development of solutions to combat persistent and potentially deadly strains of Influenza, COVID19, and other viruses. Teresa’s career spans 20 years in the healthcare industry, including health technology executive, life sciences investor, and clinical pharmacist. She has brought multiple successful life-changing healthcare products to market. Read more >>

Tech 50 2020: Honoring Pittsburgh’s Top Technology Companies

Ziad2022-11-25T14:02:05-05:00 The Pittsburgh Technology Council's annual Tech 50 Awards honored technology innovation in the Pittsburgh region with a virtual gala event on Nov. 12, 2020. List includes CytoAgents CEO Teresa Whalen, RPh was selected as a finalist for Pittsburgh Technology Council's #TECH50 “CEO of the Year.” Read more >>

ALung and CytoAgents CEOs talk pandemic’s impact on funding, trials

Ziad2022-11-25T14:02:05-05:00 At 3 Rivers Venture Fair, panel discussion, CEOs address what happened when they changed direction due to Covid-19. Including CytoAgents. Read more >>

Pittsburgh-based CytoAgents with Covid innovation starts clinical trials

Ziad2022-11-25T14:02:27-05:00 CytoAgents, a Pittsburgh-based pharmaceutical company whose drug candidate battles a deadly side effect of respiratory illnesses like Covid-19, has reached the phase-one clinical trial stage. Read more >>

Local Biotech Firm Develops Drug For Respiratory Distress In COVID-19 Patients

Ziad2022-11-25T14:02:27-05:00 Pittsburgh-based biotech company CytoAgents is launching into phase one of clinical trials this month on a drug designed to treat people with COVID-19 who develop serious respiratory distress when their immune system overreacts to the virus. Read more >>